Cytokines, obesity, and cancer: New insights on mechanisms linking obesity to cancer risk and progression

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 45-57

  Gilbert, Candace A ^a   Slingerland, Joyce M ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

adipocytes; body mass index; breast cancer; metastasis

Indexed keywords

ADIPONECTIN; AROMATASE; CHECKPOINT KINASE 1; CYTOKINE; EPIDERMAL GROWTH FACTOR; ESTROGEN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NOTCH3 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RANTES; SOMATOMEDIN C; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADIPOCYTE; ADIPOSE TISSUE; ANGIOGENESIS; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL ADHESION; CELL INTERACTION; CELL INVASION; CELL MOTILITY; CELL RENEWAL; COLON CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; EPIDEMIC; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; HYPOXIA; KIDNEY CANCER; LYMPH NODE METASTASIS; METASTASIS; MORBIDITY; NEOPLASM; NONHUMAN; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROADIPOCYTE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UNITED STATES; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

BODY MASS INDEX; CYTOKINES; DISEASE PROGRESSION; HUMANS; INCIDENCE; NEOPLASMS; OBESITY; RISK FACTORS; WORLD HEALTH;

EID: 84873030540     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-121211-091527     Document Type: Review

References (100)

1. World Health Organization. 2011. Obesity and Overweight-Fact Sheet #311 (updated February 2011). http://www.who.int/mediacentre/factsheets/fs311/en/
2. Calle EE, Rodriguez C, Walker-Thurmond K, et al. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J Med. 348:1625-38
3. Bergstrom A, Pisani P, Tenet V, et al. 2001. Overweight as an avoidable cause of cancer in Europe. Int. J. Cancer 91:421-30
4. Murphy TK, Calle EE, Rodriguez C, et al. 2000. Body mass index and colon cancer mortality in a large prospective study. Am. J. Epidemiol. 152:847-54
5. Wright ME, Chang SC, Schatzkin A, et al. 2007. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109:675-84
6. Fader AN, Arriba LN, Frasure HE, et al. 2009. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol. Oncol. 114:121-27
7. DeSantis C, Siegel R, Bandi P, et al. 2011. Breast cancer statistics, 2011. CA Cancer J. Clin. 61:409-18
8. Carmichael AR. 2006. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG Int. J. Obstet. Gynaecol. 113:1160-66
9. Eliassen AH, Colditz GA, Rosner B, et al. 2006. Adult weight change and risk of postmenopausal breast cancer. JAMA 296:193-201
10. Ursin G, Longnecker MP, Haile RW, et al. 1995. A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology 6:137-41
11. Haakinson DJ, Leeds SG, Dueck AC, et al. 2012. The impact of obesity on breast cancer: a retrospective review. Ann. Surg. Oncol. 19:3012-18
12. Protani M, Coory M, Martin JH. 2010. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res. Treat. 123:627-35
13. van Kruijsdijk RC, van der Wall E, Visseren FL. 2009. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev. 18:2569-78
14. Maiti B, Kundranda MN, Spiro TP, et al. 2010. The association of metabolic syndrome with triplenegative breast cancer. Breast Cancer Res. Treat. 121:479-83
15. Patterson RE, Cadmus LA, Emond JA, et al. 2010. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas 66:5-15
16. Lin EY, Pollard JW. 2007. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67:5064-66
17. Vona-Davis L, Rose DP. 2009. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev. 20:193-201
18. Roberts DL, Dive C, Renehan AG. 2010. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu. Rev. Med. 61:301-16
19. Gesta S, Tseng YH, Kahn CR. 2007. Developmental origin of fat: tracking obesity to its source. Cell 131:242-56
20. Rajala MW, Scherer PE. 2003. Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765-73
21. Simons PJ, van den Pangaart PS, van Roomen CP, et al. 2005. Cytokine-mediated modulation of leptin and adiponectin secretion during in vitro adipogenesis: evidence that tumor necrosis factor-alpha- and interleukin-1beta-treated human preadipocytes are potent leptin producers. Cytokine 32:94-103
22. ZeydaM, GollingerK, Kriehuber E, et al. 2010. Newly identified adipose tissuemacrophage populations in obesity with distinct chemokine and chemokine receptor expression. Int. J. Obes. (Lond.) 34:1684-94
23. Campbell MJ, Tonlaar NY, Garwood ER, et al. 2010. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res. Treat. 128:703-11
24. Naugler WE, Karin M. 2008. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14:109-19
25. Balistreri CR, Caruso C, Candore G. 2010. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediat. Inflamm. 2010:1-19
26. Lago F, Gomez R, Gomez-Reino JJ, et al. 2009. Adipokines as novel modulators of lipid metabolism. Trends Biochem. Sci. 34:500-10
27. Guzik TJ, Mangalat D, Korbut R. 2006. Adipocytokines-novel link between inflammation and vascular function? J. Physiol. Pharmacol. 57:505-28
28. Tilg H, Moschen AR. 2006. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6:772-83
29. Berg AH, Scherer PE. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96:939-49
30. Ryan AS, Berman DM, Nicklas BJ, et al. 2003. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 26:2383-88
31. Kelesidis I, Kelesidis T, Mantzoros CS. 2006. Adiponectin and cancer: a systematic review. Br. J. Cancer 94:1221-25
32. Grossmann ME, Ray A, Nkhata KJ, et al. 2010. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev. 29:641-53
33. Dalamaga M, Diakopoulos KN, Mantzoros CS. 2012. The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 33:547-94
34. Cirillo D, Rachiglio AM, la Montagna R, et al. 2008. Leptin signaling in breast cancer: an overview. J. Cell Biochem. 105:956-64
35. Lumeng CN, Bodzin JL, Saltiel AR. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117:175-84
36. Park EJ, Lee JH, Yu GY, et al. 2010. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208
37. Keophiphath M, RouaultC, Divoux A, et al. 2010. CCL5 promotesmacrophage recruitment and survival in human adipose tissue. Arterioscler. Thromb. Vasc. Biol. 30:39-45
38. Poulain-Godefroy O, Froguel P. 2007. Preadipocyte response and impairment of differentiation in an inflammatory environment. Biochem. Biophys. Res. Commun. 356:662-67
39. Soria G, Ben-Baruch A. 2008. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267:271-85
40. Waugh DJ, Wilson C. 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14:6735-41
41. Bendre MS, Gaddy-KurtenD, Mon-FooteT, et al. 2002. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62:5571-79
42. De Larco JE, Wuertz BR, Rosner KA, et al. 2001. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am. J. Pathol. 158:639-46
43. Chavey C, Bibeau F, Gourgou-Bourgade S, et al. 2007. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 9:R15
44. Knupfer H, Preiss R. 2007. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 102:129-35
45. Chen J. 2011. Multiple signal pathways in obesity-associated cancer. Obes. Rev. 12:1063-70
46. Jarde T, Perrier S, Vasson MP, et al. 2011. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur. J. Cancer 47:33-43
47. Bromberg J, Wang TC. 2009. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15:79-80
48. Cabodi S, Taverna D. 2010. Interfering with inflammation: a new strategy to block breast cancer selfrenewal and progression? Breast Cancer Res. 12:305-6
49. Subbaramaiah K, Howe LR, Bhardwaj P, et al. 2011. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res. (Phila.) 4:329-46
50. Fontana L, Eagon JC, Trujillo ME, et al. 2007. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56:1010-13
51. Kalluri R, Weinberg RA. 2009.Thebasics of epithelial-mesenchymal transition. J. Clin. Invest. 119:1420-28
52. Thiery JP, Acloque H, Huang RY, et al. 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139:871-90
53. Xie G, Yao Q, Liu Y, et al. 2012. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int. J. Oncol. 40:1171-79
54. HwangWL, Yang MH, Tsai ML, et al. 2011. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 141:279-91
55. Karnoub AE, Dash AB, Vo AP, et al. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-63
56. Qian BZ, Li J, Zhang H, et al. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:222-25
57. Dirat B, Bochet L, Dabek M, et al. 2011. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71:2455-65
58. Walter M, Liang S, Ghosh S, et al. 2009. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28:2745-55
59. Tan J, Buache E, Chenard MP, et al. 2011. Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int. J. Dev. Biol. 55:851-59
60. Alessi MC, Bastelica D, Morange P, et al. 2000. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49:1374-80
61. Carter JC, Church FC. 2012. Mature breast adipocytes promote breast cancer cell motility. Exp. Mol. Pathol. 92:312-17
62. Nicolini A, Carpi A, Rossi G. 2006. Cytokines in breast cancer. Cytokine Growth Factor Rev. 17:325-37
63. De Luca A, Lamura L, Gallo M, et al. 2012. Mesenchymal stem cells-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J. Cell Biochem. 113:3363-70
64. Inoue K, Slaton JW, Eve BY, et al. 2000. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 6:2104-19
65. Benoy IH, Salgado R, van DP, et al. 2004. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10:7157-62
66. Charafe-Jauffret E, Ginestier C, Iovino F, et al. 2009. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69:1302-13
67. Magee JA, Piskounova E, Morrison SJ. 2012. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:283-96
68. O'Brien CA, Kreso A, Dick JE. 2009. Cancer stem cells in solid tumors: an overview. Semin. Radiat. Oncol. 19:71-77
69. Quintana E, ShackletonM, Sabel MS, et al. 2008. Efficient tumour formation by single human melanoma cells. Nature 456:593-98
70. Al Hajj M, Wicha MS, Benito-Hernandez A, et al. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100:3983-88
71. Ginestier C, Hur MH, Charafe-Jauffret E, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-67
72. Li X, LewisMT, Huang J, et al. 2008. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100:672-79
73. Balic M, Lin H, Young L, et al. 2006. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12:5615-21
74. ShafeeN, Smith CR, Wei S, et al. 2008. Cancer stem cells contribute to cisplatin resistance in Brca1/p53- mediated mouse mammary tumors. Cancer Res. 68:3243-50
75. Calcagno AM, Salcido CD, Gillet JP, et al. 2010. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Natl. Cancer Inst. 102:1637-52
76. Tanei T, Morimoto K, Shimazu K, et al. 2009. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 15:4234-41
77. Korkaya H, Liu S, Wicha MS. 2011. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Invest. 121:3804-9
78. Razmkhah M, Jaberipour M, Hosseini A, et al. 2010. Expression profile of IL-8 and growth factors in breast cancer cells and adipose-derived stem cells (ASCs) isolated from breast carcinoma. Cell Immunol. 265:80-85
79. Ginestier C, Liu S, Diebel ME, et al. 2010. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120:485-97
80. Marotta LL, Almendro V, Marusyk A, et al. 2011. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121:2723-35
81. Liu S, Ginestier C, Ou SJ, et al. 2011. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71:614-24
82. Sansone P, Storci G, Tavolari S, et al. 2007. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117:3988-4002
83. Iliopoulos D, Hirsch HA, Struhl K. 2009. An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139:693-706
84. Iliopoulos D, Hirsch HA, Wang G, et al. 2011. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 108:1397-402
85. D'Anello L, Sansone P, Storci G, et al. 2010. Epigenetic control of the basal-like gene expression profile via interleukin-6 in breast cancer cells. Mol. Cancer 9:300-13
86. Wang Y, Yu Y, Tsuyada A, et al. 2011. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 30:1470-80
87. AsieduMK, Ingle JN, BehrensMD, et al. 2011. TGFβ/TNFα-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 71:4707-19
88. ZhengQ, Dunlap SM, Zhu J, et al. 2011. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr. Relat Cancer 18:491-503
89. IshikawaM, Kitayama J, Nagawa H. 2004. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin. Cancer Res. 10:4325-31
90. Guo S, Liu M, Wang G, et al. 2012. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim. Biophys. Acta 1825:207-22
91. FeldmanDE, Chen C, Punj V, et al. 2012. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc. Natl. Acad. Sci. USA 109:829-34
92. Todaro M, Alea MP, Di Stefano AB, et al. 2007. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1:389-402
93. Wang L, Liu Z, Balivada S, et al. 2012. Interleukin-1beta and transforming growth factor-beta cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res. Ther. 3:5
94. Kao AP, Wang KH, Long CY, et al. 2011. Interleukin-1beta induces cyclooxygenase-2 expression and promotes the invasive ability of human mesenchymal stem cells derived from ovarian endometrioma. Fertil. Steril. 96:678-84
95. Behan JW, Yun JP, Proektor MP, et al. 2009. Adipocytes impair leukemia treatment in mice. Cancer Res. 69:7867-74
96. Bochet L, Meulle A, Imbert S, et al. 2011. Cancer-associated adipocytes promotes breast tumor radioresistance. Biochem. Biophys. Res. Commun. 411:102-6
97. PhillipsTM, McBrideWH, Pajonk F. 2006. The response ofCD24-/low/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98:1777-85
98. Creighton CJ, Li X, Landis M, et al. 2009. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 106:13820-25
99. Levina V, Marrangoni AM, DeMarco R, et al. 2008. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 3:e3077
100. De Larco JE, Wuertz BR, Manivel JC, et al. 2001. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res. 61:2857-61